Sign inJoin waitlistJoin the waitlist

Sani Kizilbash

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Medical Oncology
2006–2008
Internal Medicine
2003–2006
Doctor of Medicine
1999–2003

Research

Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data
Review · Neuro-Oncology · 2018 · 581 citations
Delineation of MGMT Hypermethylation as a Biomarker for Veliparib-Mediated Temozolomide-Sensitizing Therapy of Glioblastoma
Journal of the National Cancer Institute · 2016 · 110 citations
Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System
Molecular Cancer Therapeutics · 2015 · 76 citations

Terry Burns
28 papers
Jann Sarkaria
22 papers
Michael Ruff
21 papers
Ugur Sener
18 papers
Joon Uhm
17 papers
Bryan Neth
15 papers · 3 as a resident
Jian Campian
14 papers
William Breen
12 papers · 2 as a resident
Nadia Laack
11 papers
Paul Brown
11 papers
Timothy Kaufmann
11 papers
CG
Caterina Giannini
10 papers

Grants

Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of WSD0922-FU
Food and Drug Administration · R01
Contact PI · $882K · Mayo Clinic Rochester
2021–2026

Clinical trials

Temozolomide, With or Without WSD0922-FU, for the Treatment of EGFR-Mutant, IDH-Wildtype Glioblastoma
Principal investigator · Suspended · Phase 2
Mayo Clinic
2026–2036
WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System Metastases
Principal investigator · Active not recruiting · Phase 1
Mayo Clinic
2019–2031
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
Principal investigator · Active not recruiting · Phase 1
National Cancer Institute (NCI)
2019–2027
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Principal investigator · Completed · Phase 1, Phase 2
Kintara Therapeutics, Inc.
2011–2016